AP-007

Mantle cell, 65 to 74, urban, commercial, under 25 miles

CAR-T · Phase 5, Treatment · 8 days in stage · 1 barriers, 0 blocking

On track

Follow one barrier

Diagnosis & Referral

From diagnosis to first contact with an accredited center.

Any order, all required

Start ahead · work beginning here for later phases

Plan bridging early with a standardized protocol; avoid bendamustine before apheresis · Manufacturing / collection & vein-to-vein risk · for phase 4

Completion criteriaReach a centerreferred and accepted for evaluationNothing in the way for this patient

The work-up that determines whether the center will proceed. Most tests run in parallel and all feed the selection decision.

Any order, all required

Start ahead · work beginning here for later phases

Ask about early leukapheresis + cryopreservation to protect T-cell fitness · Manufacturing / collection & vein-to-vein risk · for phase 4

Completion criteriaAccepted as a candidatethe center recommends treatmentNothing in the way for this patient

Securing payer approval and financial clearance for the specific therapy.

Any order, all required

Completion criteriaApproved to proceedauthorization and coverage in placeNothing in the way for this patient

Obtaining the cells and getting the patient ready. This is where CAR-T and allogeneic transplant diverge.

CAR-T track

Shared preparation — in parallel with collection

Any order, all required

Conditioning, infusion, and the acute monitoring window.

Completion criteriaThrough the acute phaseinfusion complete, early toxicity managedNothing in the way for this patient

Monitoring, transition back home, and long-term survivorship.